BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
FDA agreed that the ongoing CardiAMP HF II trial may be sufficient to support approval of the therapy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (BCDA) will present the CardiAMP HF II trial design at the HFSA Annual Scientific Meeting on October 9–12, 2026.
The Phoenix presentation covers the design and scientific support for the ongoing multicenter, double-blind randomized controlled trial. It seeks to determine whether high-dose treatment using patients’ own cells is effective in ischemic heart failure with reduced ejection fraction, meaning reduced heart pumping capacity. Participants are receiving guideline-directed medical therapy but still have elevated biomarkers of heart stress.
FDA agreed the ongoing trial may be sufficient to support approval. FDA also approved a category B designation for the CardiAMP cell therapy system in three separate clinical trials. BioCardia said it is advancing the confirmatory trial alongside ongoing regulatory submissions to FDA and Japan’s PMDA.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFDA agreement indicates the ongoing CardiAMP HF II trial may be sufficient to support approval.
- Minor pointCategory B designation approved by FDA for the CardiAMP cell therapy system in three separate clinical trials.
- Minor pointConfirmatory CardiAMP HF II trial is advancing alongside ongoing FDA and Japan PMDA regulatory submissions.
Negative
- None.
Key Figures
- Clinical trials with category B designation
- 3 clinical trials
- CardiAMP cell therapy system
Historical Context
-
FDA indicated CardiAMP HF II could support Premarket Approval; enrollment was active at four centers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
autologous medical
rct medical
hfr ef medical
guideline directed medical therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a scientific poster entitled “Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)” at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
The presentation includes details on the design and scientific support for the CardiAMP™ HF II Study. The objective of the study is to determine efficacy of high dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF), who are on guideline directed medical therapy but still exhibit undesirable elevated biomarkers of heart stress. This presentation will become available through the Scientific Publications on BioCardia’s website.
FDA has approved a category B designation for CardiAMP cell therapy system in three separate clinical trials as they determined either the underlying questions of safety and effectiveness of the device type have been resolved or the device type can be safe and effective. FDA recently agreed that the ongoing CardiAMP HF II trial, the focus of the HFSA scientific presentation, may be sufficient to support FDA approval.
“In parallel to ongoing regulatory submissions with FDA and Japan’s PMDA related to our therapy, we are advancing the confirmatory CardiAMP HF II trial with world class centers,” said Peter Altman, PhD, BioCardia President and CEO, and member of HFSA. “At the HFSA Annual Scientific meeting this weekend we have scheduled meetings with leaders in heart failure care to discuss the evidence supporting this therapy and collaborative efforts to provide this new therapeutic option to patients who have plateaued on available therapies and may benefit from minimally invasive autologous cell therapy.”
About BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information, visit www.biocardia.com.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to the presentation and meetings planned at HFSA.
These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release.
Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials and regulatory programs. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is BioCardia’s CardiAMP HF II trial testing?
The trial seeks to determine the efficacy of high-dose treatment using patients’ own cells in ischemic heart failure with reduced ejection fraction. It targets patients receiving guideline-directed medical therapy who still have elevated biomarkers of heart stress.
Could BioCardia’s CardiAMP HF II trial support FDA approval?
FDA agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval. This is a potential regulatory path, not an announcement that the therapy has received approval.